EMA/157570/2022

European Medicines Agency decision

P/0129/2022

of 13 April 2022

on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (Fasenra), (EMEA-001214-PIP01-11-M11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0129/2022

of 13 April 2022

on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (Fasenra), (EMEA-001214-PIP01-11-M11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0126/2013 issued on 28 May 2013, decision P/0020/2014 issued on 22 January 2014, decision P/0018/2015 issued on 30 January 2015, decision P/0146/2015 issued on 10 July 2015, decision P/0283/2015 issued on 27 November 2015, decision P/0213/2016 issued on 12 August 2016, decision P/0107/2018 issued on 11 April 2018, and decision P/0244/2018 issued on 15 August 2018,

Having regard to the application submitted by AstraZeneca AB on 18 November 2021 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 25 February 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for benralizumab (Fasenra), solution for injection, subcutaneous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to AstraZeneca AB, Södertälje, SE-151 85 – Södertälje, Sweden.

EMA/PDCO/711045/2021
Amsterdam, 25 February 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001214-PIP01-11-M11

Scope of the application

Active substance(s):

Benralizumab

Invented name:

Fasenra

Condition(s):

Treatment of asthma

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

AstraZeneca AB

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, AstraZeneca AB submitted to the European Medicines Agency on 18 November 2021 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0126/2013 issued on 28 May 2013, decision P/0020/2014 issued on 22 January 2014, decision P/0018/2015 issued on 30 January 2015, decision P/0146/2015 issued on 10 July 2015, decision P/0283/2015 issued on 27 November 2015, decision P/0213/2016 issued on 12 August 2016, decision P/0107/2018 issued on 11 April 2018, and decision P/0244/2018 issued on 15 August 2018.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 4 January 2022.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of asthma

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- for solution for injection, subcutaneous use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition

Treatment of asthma

2.1.1. Indication(s) targeted by the PIP

Add on treatment for uncontrolled asthma with eosinophilic inflammation in children 6 years and older, adolescents (and adults)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection (in pre-filled syringe)

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of an age appropriate presentation (solution for injection in pre-filled syringe) to ensure that the formulation is able to cover the full range of paediatric doses.
Non-clinical studies	Not applicable.
Clinical studies	**Study 2** Multicentre, randomized, double-blind, placebo-controlled 56-week study to evaluate the efficacy and safety of subcutaneous (SC) benralizumab (MEDI-563) in adolescents (and adults) with uncontrolled asthma.

	Study 3 Multicentre, randomized, double-blind, placebo-controlled 48-week study to evaluate the efficacy and safety of subcutaneous (SC) benralizumab (MEDI-563) in adolescents (and adults) with uncontrolled asthma. **Study 4** Deleted during procedure EMEA-001214-PIP01-11-M11 **Study 5** Deleted during procedure EMEA-001214-PIP01-11-M11 **Study 6** Deleted during procedure EMEA-001214-PIP01-11-M11 **Study 7** Randomized, parallel group extension study to establish the long-term safety of two dosing regimens of subcutaneous benralizumab in adolescent (and adult) subjects with inadequately controlled asthma. **Study 8** Deleted during procedure EMEA-001214-PIP01-11-M11 **Study 9** (added during procedure EMEA-001214-PIP01-11-M04) Multicentre, randomised, double-blind, parallel group, placebo-controlled study to evaluate the effect of benralizumab on immune responses following seasonal influenza virus vaccination in adolescent patients (and young adults) with asthma. **Study 10** Added during procedure EMEA-001214-PIP01-11-M11 Uncontrolled, open-label trial to evaluate safety, tolerability and effect of body weight and age on the pharmacokinetics (PK) of benralizumab, and to assess the relationship between benralizumab exposure and pharmacodynamic (PD) response using blood eosinophils in children from 6 years to less than 12 years with severe asthma **Study 13** Added during procedure EMEA-001214-PIP01-11-M11 Randomised, double-blind, placebo-controlled trial, followed by an open-label extension phase to evaluate efficacy and safety of benralizumab in children from 6 years to less than 18 years with severe eosinophilic asthma

Extrapolation, modelling and simulation studies	**Study 11** Added during procedure EMEA-001214-PIP01-11-M11 Population pharmacokinetic (PK) model and PK/pharmacodynamic (PD) model to confirm that PK and PD profiles similar to adults are attained in children from 6 years to less than 18 years of age with severe eosinophilic asthma
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety / efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By September 2032
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of asthma

Authorised indication(s):

- Fasenra is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.

Authorised pharmaceutical form(s):

Solution for injection in pre-filled syringe (injection)

Solution for injection in pre-filled pen (injection) (Fasenra Pen)

Authorised route(s) of administration:

Subcutaneous use